ELIMINATE-AF trial in the context of other non-vitamin K antagonist oral anticoagulant trials.
Session:
Catheter ablation and anticoagulation in patients with Atrial Fibrillation (AF): where do we stand?
Topic:
Oral Anticoagulation
Speaker:
Professor J. Kautzner (Prague, CZ)
Sponsored by Daiichi Sankyo, Europe
Event:
EHRA 2019
Congress Presentation
About the speaker
Professor Josef Kautzner
Institute for Clinical and Experimental Medicine (IKEM), Prague (Czechia)
41
presentations
5
followers
4 more presentations in this session
Welcome and Introduction - Catheter ablation and anticoagulation in patients with Atrial Fibrillation (AF): where do we stand?
Speaker: Professor S. Hohnloser (Frankfurt, DE)
Implications of non-vitamin K antagonist oral anticoagulant trials in ablation practice.
Speaker: Doctor M. Grimaldi (Acquaviva Delle Fonti, IT)
Current recommendation for atrial fibrillation patients undergoing ablation.
Speaker: Professor J. Steffel (Zurich, CH)
Panel discussion and closing remarks - Catheter ablation and anticoagulation in patients with Atrial Fibrillation (AF): where do we stand?
Speaker: Professor S. Hohnloser (Frankfurt, DE)
Access the full session
Catheter ablation and anticoagulation in patients with Atrial Fibrillation (AF): where do we stand?
Speakers:
Professor J. Kautzner, Professor S. Hohnloser, Doctor M. Grimaldi, Professor J. Steffel, Professor S. Hohnloser
About the event
ESC 365 is supported by
